Added to YB: 2026-06-18
Pitch date: 2026-06-16
ADPT [neutral]
Adaptive Biotechnologies Corporation
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$2.8B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-182.80
P/E
-53.14
EV/Sales
9.26
Sector
Life Sciences Tools and Services
Category
special_situation
Show full summary:
KEDM Lite Vol. 18 - Adaptive Biotechnologies Corporation
ADPT (update): Separating MRD diagnostics & Immune Medicine units, focusing on MRD while exploring strategic/structural options for Immune Medicine; split expected by YE2026. Financing via $250M convertible-notes offering for capped-calls, $25M buybacks, OrbiMed repayment & MRD growth.
Read full article (1 min)